EGFR Learning Library Specialty Channel

EGFR

Learning Library

News

Amivantamab Plus Chemotherapy Numerically Improved OS for Patients with EGFR-Mutant, Advanced NSCLC

10/28/2024

According to second interim data from the MARIPOSA-2 trial, amivantamab plus chemotherapy numerically improved the overall survival, and significantly prolonged the post-progression outcomes among patients with EGFR-mutant non-small cell lung...

According to second interim data...

10/28/2024

APP Institute Oncology

News

Zipalertinib Demonstrated Promising Anti-Tumor Activity Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer

10/28/2024

Stephanie Holland ;

According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...

According to results from the...

10/28/2024

APP Institute Oncology

News

Novel EGFR x HER3 Bispecific Antibody-Drug Conjugate Shows Promise Among Heavily-Pretreated Patients With Advanced Urothelial Carcinoma

10/28/2024

Allison Casey ;

A novel EGFR x HER3 bispecific ADC showed encouraging antitumor activity for heavily-pretreated advanced urothelial carcinoma.

A novel EGFR x HER3 bispecific...

10/28/2024

APP Institute Oncology

Videos

First-Line Amivantamab Plus Lazertinib Demonstrates Promise in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer

10/28/2024

Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.

Benjamin Besse, MD, PhD,...

10/28/2024

APP Institute Oncology

Sarah Smith, Virginia Cancer Specialists

Videos

Post-Progression and Safety Outcomes With First-Line Amivantamab Plus Lazertinib vs Osimertinib for Advanced NSCLC: Best Management Practices

05/08/2024

Sarah Smith, BD, CNMT, discusses findings from the phase 3 MARIPOSA study exploring post-progression and safety outcomes with first-line amivantamab plus lazertinib vs osimertinib for advanced NSCLC and offers guidance for best management...

Sarah Smith, BD, CNMT, discusses...

05/08/2024

APP Institute Oncology

Rapid Refresh

Understanding the Role of EGFR in Cancer Pathogenesis

11/23/2023

This animation explains the role of EGFR in the regulation of cell growth and the effects of the overexpression of EGFR.

This animation explains the role...

11/23/2023

APP Institute Oncology

The Advanced Practice Provider (APP) Institute is a new offering from the Oncology Learning Network that provides microburst education to oncology advanced practitioners. The platform offers year-round digital non-accredited learning modules through animated short videos, multimedia interviews with key opinion leaders, interactive content to test your knowledge, and more!

EGFR Learning Library Specialty Channel

Specialties

Events

Year Round Education

HMP Global Products